163 related articles for article (PubMed ID: 21172112)
1. Impact of adjuvant chemotherapy on patients with lymph node metastasis at the time of radical cystectomy.
Guzzo TJ; Resnick MJ; Canter DJ; Balandra A; Bergey MR; Magerfleisch L; Tomaszewski JE; Vaughn DJ; Malkowicz SB
Can J Urol; 2010 Dec; 17(6):5465-71. PubMed ID: 21172112
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort.
Pouessel D; Bastuji-Garin S; Houédé N; Vordos D; Loriot Y; Chevreau C; Sevin E; Beuzeboc P; Taille A; Le Thuaut A; Allory Y; Culine S
Clin Genitourin Cancer; 2017 Feb; 15(1):e45-e52. PubMed ID: 27554584
[TBL] [Abstract][Full Text] [Related]
3. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
Sternberg CN; Skoneczna I; Kerst JM; Albers P; Fossa SD; Agerbaek M; Dumez H; de Santis M; Théodore C; Leahy MG; Chester JD; Verbaeys A; Daugaard G; Wood L; Witjes JA; de Wit R; Geoffrois L; Sengelov L; Thalmann G; Charpentier D; Rolland F; Mignot L; Sundar S; Symonds P; Graham J; Joly F; Marreaud S; Collette L; Sylvester R; ; ; ; ;
Lancet Oncol; 2015 Jan; 16(1):76-86. PubMed ID: 25498218
[TBL] [Abstract][Full Text] [Related]
4. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.
Metcalfe MJ; Ferguson JE; Li R; Xiao L; Guo CC; Czerniak BA; Siefker-Radtke A; Pretzsch SM; Navai N; McConkey DJ; Kamat AM; Campbell M; Dinney C
Eur Urol Focus; 2017 Dec; 3(6):577-583. PubMed ID: 28753816
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
Vetterlein MW; Seisen T; May M; Nuhn P; Gierth M; Mayr R; Fritsche HM; Burger M; Novotny V; Froehner M; Wirth MP; Protzel C; Hakenberg OW; Roghmann F; Palisaar RJ; Noldus J; Pycha A; Bastian PJ; Trinh QD; Xylinas E; Shariat SF; Rink M; Chun FK; Dahlem R; Fisch M; Aziz A;
Eur Urol Focus; 2018 Mar; 4(2):252-259. PubMed ID: 28753775
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC
Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776
[TBL] [Abstract][Full Text] [Related]
8. Decreased Overall and Bladder Cancer-Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis.
Froehner M; Koch R; Heberling U; Novotny V; Oehlschlaeger S; Hübler M; Baretton GB; Hakenberg OW; Wirth MP
Eur Urol; 2016 Jun; 69(6):984-7. PubMed ID: 26194042
[TBL] [Abstract][Full Text] [Related]
9. The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer.
von Deimling M; Mertens LS; Furrer M; Li R; Tendijck GAH; Taylor J; Crocetto F; Maas M; Mari A; Pichler R; Moschini M; Tully KH; D'Andrea D; Laukhtina E; Del Giudice F; Marcq G; Velev M; Gallioli A; Albisinni S; Mori K; Khanna A; Rink M; Fisch M; Minervini A; Black PC; Lotan Y; Spiess PE; Kiss B; Shariat SF; Pradere B;
BJU Int; 2024 Jul; 134(1):119-127. PubMed ID: 38470089
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of lymph-node dissection in patients undergoing radical cystectomy following previous oncological treatment for bladder cancer.
Jensen JB; Ulhøi BP; Jensen KM
Scand J Urol Nephrol; 2011 Dec; 45(6):436-43. PubMed ID: 21854099
[TBL] [Abstract][Full Text] [Related]
11. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
Ravi P; Pond GR; Diamantopoulos LN; Su C; Alva A; Jain RK; Skelton WP; Gupta S; Tward JD; Olson KM; Singh P; Grunewald CM; Niegisch G; Lee JL; Gallina A; Bandini M; Necchi A; Mossanen M; McGregor BA; Curran C; Grivas P; Sonpavde GP
BJU Int; 2021 Nov; 128(5):607-614. PubMed ID: 33909949
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
[TBL] [Abstract][Full Text] [Related]
13. Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study.
Koie T; Ohyama C; Hashimoto Y; Hatakeyama S; Yamamoto H; Yoneyama T; Kamimura N
Int J Clin Oncol; 2013 Aug; 18(4):724-30. PubMed ID: 23011100
[TBL] [Abstract][Full Text] [Related]
14. Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy.
Masson-Lecomte A; Xylinas E; Bouquot M; Sibony M; Allory Y; Comperat E; Zerbib M; de la Taille A; Rouprêt M
World J Urol; 2015 Aug; 33(8):1087-93. PubMed ID: 25179011
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.
Cognetti F; Ruggeri EM; Felici A; Gallucci M; Muto G; Pollera CF; Massidda B; Rubagotti A; Giannarelli D; Boccardo F;
Ann Oncol; 2012 Mar; 23(3):695-700. PubMed ID: 21859900
[TBL] [Abstract][Full Text] [Related]
16. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
[TBL] [Abstract][Full Text] [Related]
17. Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement.
Stöckle M; Wellek S; Meyenburg W; Voges GE; Fischer U; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
Urology; 1996 Dec; 48(6):868-75. PubMed ID: 8973669
[TBL] [Abstract][Full Text] [Related]
18. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy is possibly beneficial for locally advanced or node-positive bladder cancer.
Kanatani A; Nakagawa T; Kawai T; Naito A; Sato Y; Yoshida K; Nozaki K; Nagata M; Yamada Y; Azuma T; Suzuki M; Fujimura T; Fukuhara H; Nishimatsu H; Kume H; Igawa Y; Homma Y
Clin Genitourin Cancer; 2015 Apr; 13(2):e107-12. PubMed ID: 25456839
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy versus observation after radical cystectomy in patients with node-positive bladder cancer.
Pak S; You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Kim CS; Ahn H
Sci Rep; 2019 Jun; 9(1):8305. PubMed ID: 31165753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]